Saraswati Sukumar

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Development of the cf-MMSP assay for enhanced analytical sensitivity of methylated DNA in breast cancer liquid biopsy

  Cancer Epidemiology Biomarkers & Prevention · 2026-06-23

• CRYβB2 is a biomarker for poor prognosis and response to CDK4/6 inhibitors in breast cancer

  Breast Cancer Research · 2026-01-14

• Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial

  2025-11-25

• Supplementary Table S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial

  2025-11-25

• Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial

  2025-11-25

• Supplementary Table S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial

  2025-11-25

• Supplementary Table S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial

  2025-11-25

• Supplementary Table S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial

  2025-11-25

• Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial

  2025-11-25

• Supplementary Table S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial

  2025-11-25

• Supplementary Table S6 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial

  2025-11-25

• Supplementary Data from Nanoparticle-Based Combination Therapy Enhances Fulvestrant Efficacy and Overcomes Tumor Resistance in ER-Positive Breast Cancer

  2025-11-24

• Correction: Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer

  Oncogene · 2025-09-05

• CRYβB2 is a biomarker for poor prognosis and response to CDK4/6 inhibitors in breast cancerPreprint

  Research Square · 2025-05-07

• Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial.

  UNC Libraries · 2025-01-23

• Drug Pills Identification System using Google Gemini LLM: A Generative AI approach

  2024-12-12

• Long-term outcomes after transcatheter aortic valve implantation: derivation and validation of the long-TAVI prediction model

  European Heart Journal · 2024-10-01

• Data from Nanoparticle-based combination therapy enhances fulvestrant efficacy and overcomes tumor resistance in ER-positive breast cancerPreprint

  2024-09-16

• Supplementary Data from Nanoparticle-based combination therapy enhances fulvestrant efficacy and overcomes tumor resistance in ER-positive breast cancerPreprint

  2024-09-16

• Supplementary Data from Nanoparticle-based combination therapy enhances fulvestrant efficacy and overcomes tumor resistance in ER-positive breast cancerPreprint

  2024-09-16